Long-term prognostic role of CA-125 in noncongestive patients undergoing a cardiac transplantation

Biomark Med. 2017 Mar;11(3):239-243. doi: 10.2217/bmm-2016-0247. Epub 2017 Feb 3.

Abstract

Aim: To evaluate the possible relationship between high levels of CA-125 and long-term prognosis in chronic heart failure patients after they undergo a cardiac transplantation (CT).

Materials & methods: We retrospectively studied all patients who underwent a CT and had a previous determination of CA-125. Congestive patients and those whose survival was <1 year after CT were excluded.

Results: Of 55 patients, 23 had elevated CA-125 levels (>35 U/ml). After CT, survival was significantly inferior in this group (96.3 vs 81%, 84.9 vs 64%, 70.7 vs 32.9% at 2, 5 and 8 years, p = 0.014). CA-125 >35 U/ml was the only factor independently associated to long-term mortality (OR: 3.94; 95% CI: 1.2-12.82; p = 0.023).

Conclusion: Noncongestive patients with high levels of CA-125 had inferior long-term survival after CT.

Keywords: CA-125; carbohydrate antigen 125; cardiac transplantation; graft rejection; heart failure; prognosis; survival; tumor markers.

MeSH terms

  • Adult
  • Biomarkers / blood
  • CA-125 Antigen / blood*
  • Female
  • Follow-Up Studies
  • Graft Rejection / diagnosis*
  • Graft Rejection / mortality
  • Heart Failure / therapy*
  • Heart Transplantation* / adverse effects
  • Humans
  • Male
  • Middle Aged
  • Odds Ratio
  • Prognosis
  • Retrospective Studies
  • Survival Rate

Substances

  • Biomarkers
  • CA-125 Antigen